Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novel rhThrombin Provided in Innovative Stabilized Formulation

Published: Friday, November 01, 2013
Last Updated: Friday, November 01, 2013
Bookmark and Share
Scil Proteins and LEUKOCARE develop a stabilized recombinant human thrombin manufactured in bacteria.

Scil Proteins GmbH and LEUKOCARE AG have announced results of their strategic partnership to develop a stabilized recombinant human thrombin (rhThrombin).

The new, proprietary and highly cost-effective bacterial manufacturing process of rhThrombin is a recent in-house development of Scil Proteins. This recombinant production process does not rely on bovine or human blood derivatives and can be scaled up easily to meet market demands.

Combining rhThrombin with a formulation of LEUKOCARE’s proprietary Stabilizing and Protecting Solutions (SPS) technology results in increased stability during storage at elevated temperatures as well as during terminal sterilization by irradiation. This offers various opportunities for novel formulations and advanced functionalized medical devices.

Controlling bleeding in surgery and avoiding blood loss during surgical intervention can be managed in several ways. One being the topical application of thrombin as a haemostatic agent.

Currently there are three types of thrombin available for use in humans: bovine thrombin, human purified thrombin and only one rhThrombin which is produced in chinese hamster ovary cells.

However, bovine thrombin holds the risk of anti-thrombin antibody production in patients. A main concern regarding the use of human purified thrombin is the risk of infectious agents like viruses and limited stability.

Recombinant products are usually free of infectious agents and impurities. Clinical studies with other available rhThrombin demonstrated comparable efficacy but significantly lower immunogenicity.

The substrate was safely applied in haemorrhage control in patients with or without pre-existing anti-bovine thrombin antibodies. Hence, products with rhThrombin may offer improved safety in clinical use.

The novel stabilized rhThrombin developed by Scil Proteins and LEUKOCARE may be used in different medical applications and medical devices to control bleeding for example sponges, glues, sealants or advanced wound dressings.

“We are able to provide access to high quality rhThrombin, free of blood derived components and with a fully scalable manufacturing process in bacteria” said Dr. Ulrike Fiedler, CEO of Scil Proteins.

Michael Scholl, CEO of LEUKOCARE added “As rhThrombin protected by our SPS technology is stable during irradiation it offers the opportunity for end sterilization as common in the medical device industry and as requested by regulatory agencies.”

Scil Proteins and LEUKOCARE are currently evaluating partners in the pharmaceutical and the medical device industry for the clinical development and commercialization of the stabilized rhThrombin.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cell Cargo Ships in Near Future?
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
Researchers Can Control Genes Involved in Cancer
A new way to control the activity of a protein, that is often upregulated in cancer, has been discovered by Moffitt researchers through monoubiquitination mechanism.
Mitochondrial Role in Metastatic Cancer
Researchers have manipulated proteins, sourced from tumour cells, that are essential for maintaining tumour cells and in doing so, have significantly reduced the ability of cancer cells.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
Scientists Culture Elusive Yellowstone Microbe
ORNL scientists have successfully isolated and cultured a Yellowstone sourced acidic hot-spring based microbe.
Seeing RNA at the Nanoscale
MIT researchers have developed a new way to image proteins and RNA inside neurons of brain tissue.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!